CHCLA Files Amicus Brief in the Supreme Court in Support of Alliance for Hippocratic Medicine
For Immediate Release
April 19, 2023
For More Information Contact:
info@catholichealthalliance.
Ormond Beach, FL- On Tuesday, April 18, 2023, the Catholic Health Care Leadership Alliance (CHCLA) filed an amicus brief with the Supreme Court of the United States of America in the case of Alliance for Hippocratic Medicine, et al, v. FDA, et al. The FDA seeks to stay the April 7, 2023 order entered by the United States District Court of the Northern District of Texas that would require the FDA to remove the abortion medication, Mifepristone, from the market pending the outcome of the underlying lawsuit. The United States Court of Appeals for the 5th Circuit, on April 12, 2023, issued a partial stay of the District Court’s ruling, allowing Mifepristone to remain in use but placing restrictions on the administration of the medication. The FDA is asking the Supreme Court to stay the April 7th order during the litigation so that Mifepristone can remain on the market with no restrictions.
CHCLA, with others, filed an amicus brief with the Supreme Court arguing that the FDA’s approval of Mifepristone for abortions fails to take into account known risks associated with the medication and deprives women and girls of informed consent as required by law. A copy of the brief can be found here.
Dr. Steven White, President of CHCLA and former president of the Catholic Medical Association, released the following statement:
“The decision by US Judge Matthew Kacsmaryk exposes and holds the FDA accountable for a seriously flawed process of approval for the abortion drug mifepristone driven not by all the medical evidence nor the necessary concern for the health and safety of every pregnant woman, but by a commitment to a radical abortion ideology which has seriously undermined the integrity of the FDA. Regardless of your position on abortion, all of us should be very concerned when a federal agency tasked with protecting our welfare repeatedly fails to respond to the legitimate concerns of qualified medical professionals regarding the dangers of a particular medication or procedure it has approved. Only a thorough and transparent review of the process followed for approval of mifepristone can possibly hope to reestablish confidence in the FDA.”
If you would like to set up an interview with Dr. Steven White of CHCLA, please contact info@
###
About the Catholic Health Care Leadership Alliance
The Catholic Health Care Leadership Alliance is an alliance of faithful Catholic organizations that supports the rights of patients and professionals to receive and provide health care in accordance with the moral, ethical, and social teachings of Jesus Christ and His Church through ongoing evangelization, education, advocacy, and mutual support. For more information, please visit www.catholichealthalliance.org
